The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Pagan Douglas W. since 2017.
This trader's CIK number is 1628880.
At the time of last reporting, Pagan Douglas W. was the Chief Financial Officer of Dicerna Pharmaceuticals Inc. (stock ticker symbol DRNA).
Also see all insider trading activities at Dicerna Pharmaceuticals Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | DRNA | 0 | $0 | 0 | $0 | 8,875 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | PRTK | 0 | $0 | 2,495 | $16,891 | 0 | $0 |
| 2018 | PRTK | 0 | $0 | 34,809 | $417,261 | 0 | $0 |
| 2017 | PRTK | 0 | $0 | 12,139 | $263,920 | 0 | $0 |
1. Dicerna Pharmaceuticals Inc (DRNA)
2. Paratek Pharmaceuticals, Inc. (PRTK)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-12-15 | DRNA | Option Ex | 2,050 | .00 | 0 |
| 2021-06-15 | DRNA | Option Ex | 6,825 | .00 | 0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-02-05 | PRTK | Sale | 2,495 | 6.77 | 16,891 |
| 2018-12-12 | PRTK | Sale | 2,918 | 6.76 | 19,725 |
| 2018-10-15 | PRTK | Sale | 2,784 | 8.96 | 24,944 |
| 2018-10-03 | PRTK | Sale | 7,579 | 9.82 | 74,425 |
| 2018-04-09 | PRTK | Sale | 5,237 | 12.70 | 66,509 |
| 2018-02-05 | PRTK | Sale | 16,291 | 14.22 | 231,658 |
| 2017-07-05 | PRTK | Sale | 4,139 | 23.58 | 97,593 |
| 2017-06-19 | PRTK | Sale | 4,595 | 25.00 | 114,875 |
| 2017-02-06 | PRTK | Sale | 3,405 | 15.11 | 51,452 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Pagan Douglas W. (Chief Financial Officer of Dicerna Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.